Page 133 - Read Online

Fang et al. Cancer Drug Resist. 2025;8:42 Page 13 of 13

35. Gao J, Shi LZ, Zhao H, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell.
2016;167:397-404.e9. DOI PubMed PMC
36. Li T, Wang H, Xu J, et al. TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung
cancer. Ther Adv Med Oncol. 2021;13:17588359211038477. DOI PubMed PMC
37. Xiao W, Du N, Huang T, et al. TP53 mutation as potential negative predictor for response of anti-CTLA-4 therapy in metastatic
melanoma. EBioMedicine. 2018;32:119-24. DOI PubMed PMC
38. Yang L, Feng Y, Liu X, et al. DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in
NSCLC and melanoma. Invest New Drugs. 2025;43:199-213. DOI PubMed
39. Kortlever RM, Sodir NM, Wilson CH, et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell.
2017;171:1301-15.e14. DOI PubMed PMC
40. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision
medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79-92. DOI PubMed

Disclaimer/Publisher’s Note: All statements, opinions, and data contained in this publication are solely those of the individual author(s) and
contributor(s) and do not necessarily reflect those of OAE and/or the editor(s). OAE and/or the editor(s) disclaim any responsibility for harm to
persons or property resulting from the use of any ideas, methods, instructions, or products mentioned in the content.

© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and
reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons license, and indicate if changes were made.

126